CoChat

Identification and Characterization of B-Cell Epitopes in the DBL4ε Domain of VAR2CSA

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Malaria during pregnancy in Plasmodium falciparum endemic regions is a major cause of mortality and severe morbidity. VAR2CSA is the parasite ligand responsible for sequestration of Plasmodium falciparum infected erythrocytes to the receptor chondroitin sulfate A (CSA) in the placenta and is the leading candidate for a placental malaria vaccine. Antibodies induced in rats against the recombinant DBL4ε domain of VAR2CSA inhibit the binding of a number of laboratory and field parasite isolates to CSA. In this study, we used a DBL4ε peptide-array to identify epitopes targeted by DBL4ε-specific antibodies that inhibit CSA-binding of infected erythrocytes. We identified three regions of overlapping peptides which were highly antigenic. One peptide region distinguished itself particularly by showing a clear difference in the binding profile of highly parasite blocking IgG compared to the IgG with low capacity to inhibit parasite adhesion to CSA. This region was further characterized and together these results suggest that even though antibodies against the synthetic peptides which cover this region did not recognize native protein, the results using the mutant domain suggest that this linear epitope might be involved in the induction of inhibitory antibodies induced by the recombinant DBL4ε domain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0043663

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Correlation between the ability of different DBL4ε anti-sera to react with native VAR2CSA expressed on infected erythrocytes (IE) and their ability to inhibit the binding of VAR2CSA-expressing FCR3 IE to CSA. (A) Anti-DBL4ε sera (n = 75) from rats were tested for reactivity in FACS and for ability to inhibit parasite binding to CSA in a static binding assay. (B) Comparison of anti-VAR2CSA antibody levels in sera which inhibited binding (N = 15) and sera without anti-binding activity (N = 9). Antibody mean titre was determined as EC50 using GraphPad Prism5.
Figure 1 Correlation between the ability of different DBL4ε anti-sera to react with native VAR2CSA expressed on infected erythrocytes (IE) and their ability to inhibit the binding of VAR2CSA-expressing FCR3 IE to CSA. (A) Anti-DBL4ε sera (n = 75) from rats were tested for reactivity in FACS and for ability to inhibit parasite binding to CSA in a static binding assay. (B) Comparison of anti-VAR2CSA antibody levels in sera which inhibited binding (N = 15) and sera without anti-binding activity (N = 9). Antibody mean titre was determined as EC50 using GraphPad Prism5.CC BY · PubMed Central
Figure 2 Reactivity of anti-sera to 62 overlapping DBL4ε peptides measured by ELISA. (A) Reactivity of DBL4ε anti-sera to each peptide is shown as the average O.D. values for the inhibitory anti-sera (black line n = 47), and the non-inhibitory anti-sera (grey line n = 28). The red circle highlights the largest region of consecutive peptides with the highest difference in peptide binding of the binding inhibitory anti sera and the non-inhibitory anti-sera. (B) O.D. values for reactivity of human sera from hyper-immune women (n = 6) to each of the 62 overlapping peptides covering the DBL4ε-FCR3 domain. Each colored line represents one female sera sample.
Figure 2 Reactivity of anti-sera to 62 overlapping DBL4ε peptides measured by ELISA. (A) Reactivity of DBL4ε anti-sera to each peptide is shown as the average O.D. values for the inhibitory anti-sera (black line n = 47), and the non-inhibitory anti-sera (grey line n = 28). The red circle highlights the largest region of consecutive peptides with the highest difference in peptide binding of the binding inhibitory anti sera and the non-inhibitory anti-sera. (B) O.D. values for reactivity of human sera from hyper-immune women (n = 6) to each of the 62 overlapping peptides covering the DBL4ε-FCR3 domain. Each colored line represents one female sera sample.CC BY · PubMed Central
Figure 3 Mapping peptide-region on the DBL4ε model and sequence alignment. (A) Peptide-region P22–P26 mapped on a DBL4ε-FCR3 model. (B) FCR3 and 3D7 sequences aligned with 3 peptides produced for immunization.
Figure 3 Mapping peptide-region on the DBL4ε model and sequence alignment. (A) Peptide-region P22–P26 mapped on a DBL4ε-FCR3 model. (B) FCR3 and 3D7 sequences aligned with 3 peptides produced for immunization.CC BY · PubMed Central
Figure 4 Reactivity of peptide-specific antibodies with the homologous peptide, recombinant DBL4ε and full-length VAR2CSA (FV2) from FCR3. (A) Serial two-fold dilution of rat antibodies specific for Pep1, Pep2 and Pep3 was tested in ELISA against the homologous peptide (B) and the recombinant proteins: DBL4ε-FCR3 and (C) FV2-FCR3.
Figure 4 Reactivity of peptide-specific antibodies with the homologous peptide, recombinant DBL4ε and full-length VAR2CSA (FV2) from FCR3. (A) Serial two-fold dilution of rat antibodies specific for Pep1, Pep2 and Pep3 was tested in ELISA against the homologous peptide (B) and the recombinant proteins: DBL4ε-FCR3 and (C) FV2-FCR3.CC BY · PubMed Central
Figure 5 Reactivity of peptide-specific antibodies against native VAR2CSA and their ability to inhibit binding of VAR2CSA expressing infected erythrocytes to CSA. (A) Reactivity against native VAR2CSA expressed on the surface of FCR3-IE was measured by flow cytometry and is presented as the ratio of the negative control. A ratio >1.5 is considered positive, indicated with the red broken line. (B) Inhibition of parasite binding to CSA using sera (1∶10 dilution) from rats immunized with a KLH-conjugated peptide or DBL4ε-FCR3. Inhibition/binding is presented as the ratio of binding compared to the negative control (sera specific for a non-VAR2CSA protein, DBL3γVAR1) ((Binding [test sample])/(Binding [negative control])). Binding values below 0.35 is considered as inhibitory and indicated by the red broken line.
Figure 5 Reactivity of peptide-specific antibodies against native VAR2CSA and their ability to inhibit binding of VAR2CSA expressing infected erythrocytes to CSA. (A) Reactivity against native VAR2CSA expressed on the surface of FCR3-IE was measured by flow cytometry and is presented as the ratio of the negative control. A ratio >1.5 is considered positive, indicated with the red broken line. (B) Inhibition of parasite binding to CSA using sera (1∶10 dilution) from rats immunized with a KLH-conjugated peptide or DBL4ε-FCR3. Inhibition/binding is presented as the ratio of binding compared to the negative control (sera specific for a non-VAR2CSA protein, DBL3γVAR1) ((Binding [test sample])/(Binding [negative control])). Binding values below 0.35 is considered as inhibitory and indicated by the red broken line.CC BY · PubMed Central
Figure 6 Antibody response of sera specific for wild-type DBL4ε-ID4 and the mut-DBL4ε. Serial two-fold dilution of rat anti-DBL4 and anti-mut-DBL4 polyclonal sera (initial dilution: 1/100) tested in ELISA against recombinant DBL4-FCR3. Antibody mean titer was determined as EC50 using GraphPad Prism5.
Figure 6 Antibody response of sera specific for wild-type DBL4ε-ID4 and the mut-DBL4ε. Serial two-fold dilution of rat anti-DBL4 and anti-mut-DBL4 polyclonal sera (initial dilution: 1/100) tested in ELISA against recombinant DBL4-FCR3. Antibody mean titer was determined as EC50 using GraphPad Prism5.CC BY · PubMed Central
Figure 7 Antibody reactivity against native VAR2CSA expressed on the surface of FCR3-IE and inhibition of FCR3-IE adhesion to CSA. (A) Anti-sera from rat immunized with either wild-type DBL4ε-FCR3 or mut-DBL4ε-FCR3 were tested for reactivity against native VAR2CSA expressed on the surface of FCR3-IE using FACS (IFA) (ratio to negative control). Pre-immune sample was used as negative control. A ratio >1.5 is considered positive, indicated with the red broken line. (B) Anti-sera (1∶10 dilution) from rat immunized with either DBL4ε or mut-DBL4ε were tested using FCR3-IE for the ability to inhibit the binding to CSA in a 96-well plate assay. The data is the ratio of binding compared to negative control (DBL3γVAR1). ((Binding [test sample])/(Binding [negative control])). Binding values below 0.35 is considered as inhibitory and indicated by the red broken line.
Figure 7 Antibody reactivity against native VAR2CSA expressed on the surface of FCR3-IE and inhibition of FCR3-IE adhesion to CSA. (A) Anti-sera from rat immunized with either wild-type DBL4ε-FCR3 or mut-DBL4ε-FCR3 were tested for reactivity against native VAR2CSA expressed on the surface of FCR3-IE using FACS (IFA) (ratio to negative control). Pre-immune sample was used as negative control. A ratio >1.5 is considered positive, indicated with the red broken line. (B) Anti-sera (1∶10 dilution) from rat immunized with either DBL4ε or mut-DBL4ε were tested using FCR3-IE for the ability to inhibit the binding to CSA in a 96-well plate assay. The data is the ratio of binding compared to negative control (DBL3γVAR1). ((Binding [test sample])/(Binding [negative control])). Binding values below 0.35 is considered as inhibitory and indicated by the red broken line.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 11

Metadata

Authors
Ditlev, S. B., Nielsen, M. A., Resende, M., Agerbæk, M. Ø., Pinto, V. V., Andersen, P. H., Magistrado, P., Lusingu, J., Dahlbäck, M., Theander, T. G., & Salanti, A.
Affiliations
University of Copenhagen (DK)
Corresponding author
Salanti, Ali
Venue
PLoS ONE
Published
2012-09-06
Volume
7
Issue
9
Pages
e43663
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2041056844
Cited by
11
References
23
Citations by year
2025: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2019: 1 · 2017: 2 · 2015: 3 · 2013: 1
FWCI
1.24
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
Højteknologifonden
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
VAR2CSA, B-cell epitopes, placental malaria, Plasmodium falciparum, chondroitin sulfate A, parasite sequestration, linear epitopes, peptide arrays, inhibitory antibodies, erythrocyte adhesion
MeSH terms
Amino Acid Sequence, Animals, Antibodies, Protozoan, Antibody Formation, Antibody Specificity, Antigens, Protozoan, Cell Adhesion, Erythrocytes, Female, Humans, Immune Sera, Models, Molecular, Molecular Sequence Data, Parasites, Peptides, Plasmodium falciparum, Pregnancy, Multivariate Analysis, Linear Models, Sequence Alignment, Protein Structure, Tertiary, Epitope Mapping, Epitopes, B-Lymphocyte, Mutant Proteins, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.